bpc-157 fda warning news today panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers A controversial new FDA panel

William Seeds explains what is happening in his book Peptide Protocols Volume 1: [AOD-9604] is unable to induce dimerization and thereby activation of the receptor (no competition with HGH) This fragment holds the fat-reducing and tissue repair sequence and mimics the effect of HGH on lipid metabolism, without having growth-promoting or pro-diabetic effects [AOD-9604] inhibits lipoprotein lipase activity in adipose tissue, stimulating lipolysis in adipocytes Since AOD-9604 does not interact with growth hormone receptors, it means the peptide has the following advantages over HGH: Does not increase IGF-1 production Does not induce insulin resistance Does not stimulate muscle growth Since beta-3-adrenergic receptor activation appears to be a secondary mechanism of the AOD-9604 peptide, its primary and complete mechanism for fat mobilization and/or fat cell death within adipose tissue is not currently known

All the patients were examined by extracranial and transcranial color-coded duplex sonography

We might expect that even broader variety of resistance mechanisms would be revealed were it to be used in clinical settings

However, pharmaceutical BMP products expensive ($5,000-$10,000 per treatment) and carry side effects (ectopic bone formation, inflammation)